Artelo Biosciences Calls White House CBD Program a Significant Milestone

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Dec 23 2025

0mins

Artelo Biosciences commented on the White House's recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol, CBD, products. Artelo views the Administration's action as a "significant milestone" in the recognition of CBD's therapeutic potential. The Company believes the federal government's "emphasis on data collection to inform future research and potential expansion to Medicaid and broader patient populations highlights a growing demand for safe, effective, and well-characterized CBD therapies," the company said.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like ARTL with instant alerts to capture every critical market movement.

ARTL

$1.68+Infinity%1D

Analyst Views on ARTL

About ARTL

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.